Summary & Overview
HCPCS J0716: Centruroides Immune F(ab)2 Injection, up to 120 mg
HCPCS Level II code J0716 denotes an injectable immune preparation: centruroides immune F(ab)2, up to 120 mg. This code identifies a parenteral biologic used in acute care settings for neutralizing specific toxins or venoms. Nationally, accurate coding of such therapies affects clinical billing, reimbursement consistency, and tracking of specialty biologic use.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise account of what the code represents, typical sites of service, and the clinical context for administration. The publication outlines benchmark considerations for billing lines, common modifiers and operational coding details, and the policy and coverage themes payers consider when adjudicating claims for specialty immune products.
This analysis provides clinicians, billing professionals, and policy stakeholders with a clear reference for how J0716 is described, where it is most often administered, and which national payers commonly manage coverage. Data not available in the input is noted where applicable; the focus remains on practical coding identification, payer scope, and the clinical service represented by the code.
Billing Code Overview
HCPCS Level II code J0716 describes an injectable immune preparation: injection, centruroides immune f(ab)2, up to 120 milligrams. The code represents a biologic, antivenom-style immune product supplied for parenteral administration.
-
Service type: Injection of an immune (antibody) preparation
-
Typical site of service: Hospital or outpatient infusion clinic where parenteral biologic therapies are administered
Clinical & Coding Specifications
Clinical Context
A patient presents to an outpatient allergy/immunology or emergency department setting with a documented bite or suspected envenomation from a North American insect or arachnid for which a Centruroides (scorpion) immune F(ab')2 antivenom is indicated. Typical presentation includes progressive local pain, paresthesia, autonomic signs (salivation, rhinorrhea), agitation, or neuromuscular symptoms such as muscle twitching, dysarthria, or respiratory compromise. Initial evaluation includes vital signs, focused neurologic and respiratory exams, and intravenous access. The antivenom, billed with J0716 (Injection, centruroides immune f(ab)2, up to 120 milligrams), is reconstituted and administered intravenously per product dosing guidelines, often in an observation unit or inpatient bed depending on severity. Monitoring includes continuous cardiac and respiratory observation, assessment for allergic/anaphylactic reactions during and after infusion, and documentation of administered lot numbers and vial counts. Supportive therapies (oxygen, benzodiazepines for agitation or muscle spasms, analgesia) are provided as needed. Post-administration observation usually lasts several hours to ensure symptom resolution and to watch for recurrent or delayed toxicity. Disposition decisions (discharge with follow-up vs. admission) are based on clinical response and airway/respiratory status.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |